Impax Generics Company Intelligence Report

Date: January 22, 2011
Pages: 18
Price:
US$ 340.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: IB692184EFCEN
Leaflet:

Download PDF Leaflet

Impax Generics Company Intelligence Report
Impax Laboratories, headquartered in Hayward, California, has existed in its present form since December 1999.

Impax focuses on the development and commercialisation of generic and branded pharmaceuticals. Its generics are marketed through Impax' Global Pharmaceuticals division, whilst branded drugs are marketed through the Impax Pharmaceuticals division. The firm markets and sells its products within the continental United States and in Puerto Rico.

Impax entered into a Strategic Alliance with Teva in June 2001. Problems with recognising revenues from the alliance have caused Impax headaches, with the firm unable to file any financial results for 2004 through to 2007 with the SEC. This led to a cessation of trading in Impax' common stock which lasted until December 2008. Impax has now begun to file results for the missing years.

For the year ended 31st December 2009, Impax reported total revenues worth US$358.4 million, up by 70.6% over the US$210.1 million reported a year earlier. Net income rose by 213.1% to US$50.1 million. Impax cited increased Global Product sales for the increase.

EXECUTIVE SUMMARY

INTRODUCTION

Rx Partner and OTC Partner Alliance Agreements
Impax Laboratories: Partner agreement gross revenues, in US$000s
Rx Partner Alliance Agreement
Teva Agreement
DAVA Agreement
Putney Agreement
OTC Partner Alliance Agreements
PRODUCTS

Impax Laboratories ANDA Approvals, January 2002 – September 2010
Recent Product Approvals
Fexofenadine and pseudoephedrine
Oxymorphone
Tamsulosin
Adderall XR authorised generic
Divalproex

FINANCIAL RESULTS

Latest Quarterly Results, Q310
Impax Laboratories: consolidated quarterly results, in US$000s
Latest Yearly Results, Year Ended 31st December 2009
Impax Laboratories: consolidated fiscal year results, in US$000s
Sales by division
Impax Laboratories: consolidated sales by division, in US$000s

MAJOR DEVELOPMENTS

Impax completes carbidopa-levodopa trial enrolment
Mergers, Acquisitions and Agreements
Impax and Perrigo enter development agreement
Impax enters into development and supply agreement with IGI Laboratories
Impax acquires products through Watson / Arrow acquisition
IMPAX to co-promote Wyeth's MDD product
Litigation
Shire receives guanfacine Paragraph IV notice from Impax; pair clash over Adderall supplies
Impax challenges ezetimibe / simvastatin patent
Impax and Watson challenge sevelamer patents
Impax and Endo settle oxymorphone litigation
Impax initiates fenofibrate patent challenge
Impax initiates choline fenofibrate patent challenge
Impax confirms colesevelam patent challenge
Impax initiates fenofibrate patent challenge
Impax confirms doxycycline patent challenge

CONTACT DETAILS
Skip to top


Ask Your Question

Impax Generics Company Intelligence Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: